Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Review objectives Are there any novel biomarkers for detection and diagnosis of intrathoracic cancers that are suitable for use in primary care? To address this review question, we will identify and describe existing validated biomarkers for the detection/diagnosis of intrathoracic (primary lung/bronchus/trachea, mesothelioma, and thymoma) cancers, focusing on their: • Diagnostic performance across different population groups (such as setting, symptomatology, health behaviors, or other patient characteristics) • Classification based on sample source (such as blood, saliva, breath, or sputum) and molecular function (such as proteins, volatile organic compounds, microRNAs, and others) • Potential relevance to populations such as primary care where cancer prevalence is low compared to specialist settings.

More information Original publication

DOI

https://www.crd.york.ac.uk/PROSPERO/view/CRD42022382874

Type

Journal article

Journal

PROSPERO (International prospective register of systematic reviews)

Publication Date

09/12/2022

Addresses

Richard Neal and Fiona Walter are funded by an NIHR School for Primary Care Research (SPCR) grant no. 577

Keywords

biomarkers, lung cancer, mesothelioma, thymoma, diagnosis, detection, Thoracic cancers, tracheal cancer